Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

StemCells Inc (NASDAQ:STEM)

1.61
Delayed Data
As of Aug 26
 +0.05 / +3.21%
Today’s Change
0.33
Today|||52-Week Range
7.56
-67.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$19.3M

Company Description

StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA.

Contact Information

StemCells, Inc.
7707 Gateway Boulevard
Newark California 94560
P:(510) 456-4000
Investor Relations:

Employees

Shareholders

Other institutional4.11%
Mutual fund holders1.48%
Individual stakeholders0.31%

Top Executives

Ken StrattonPresident, Secretary & General Counsel
Ann TsukamotoEVP-Scientific & Strategic Alliances
Stephen HuhnChief Medical Officer & VP-Clinical Research
Mohammad A. El-KalayVice President-Process Development
Naymisha PatelVice President-Quality Systems